On March 30, 2022, IGM Biosciences, Inc. announced the pricing of its underwritten public offering of 8,695,653 shares of its non-voting common stock at a price to the public of $23.00 per share. IGM also granted the underwriters a 30-day option to purchase up to an additional 1,304,347 shares of its voting common stock at a public offering price of $23.00, less underwriting discounts and commissions, which option was fully exercised on March 30, 2022. IGM received total gross proceeds of approximately $230 million from this offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by IGM. The offering closed on April 1, 2022. Wilson Sonsini Goodrich & Rosati advised IGM on the transaction.

The Wilson Sonsini team included Tony Jeffries, Jennifer Knapp, James Babikian, Zack Lenox, Ria Kuruvilla, and Joan Moses.

For more information, please see IGM’s press release.